BIIB's sNDA for Higher Dose of SMA Drug Spinraza Gets FDA's CRL

Biogen received an FDA Complete Response Letter (CRL) for its higher-dose Spinraza sNDA, requesting Chemistry, Manufacturing, and Controls (CMC) updates rather than citing clinical data deficiencies; the company plans a swift resubmission. This regulatory setback comes as Spinraza faces increasing competition, which led to an 8.5% sales decline in Q2 2025 and a flat global revenue outlook for 2025, despite the higher dose's potential for improved patient outcomes and its recent approval in Japan.

Analysis

Biogen has encountered a regulatory setback with the FDA issuing a Complete Response Letter (CRL) for its supplemental new drug application (sNDA) for a higher-dose regimen of Spinraza. Critically, the CRL pertains to a request for updated Chemistry, Manufacturing, and Controls (CMC) information and does not cite deficiencies in the clinical data, which was supported by the positive primary endpoint from the Phase II/III DEVOTE study. This suggests the issue is procedural and likely resolvable, as underscored by the company's plan for a swift resubmission. However, this delay in the U.S. market occurs within a challenging competitive context. Spinraza sales are already under pressure, having declined 8.5% in the second quarter of 2025 due to competition from Novartis' Zolgensma and Roche's Evrysdi. The company's guidance for flat global Spinraza revenues in 2025 now faces increased risk, especially with the second half of the year projected to be weaker. The stock's 8.9% year-to-date loss, contrasting with the industry's 4.3% gain, reflects existing investor concerns that this news will likely amplify. While the recent approval of the higher dose in Japan provides some validation, the U.S. delay cedes a tactical advantage to competitors in a key market.

Key Decisions for Investors

• Investors should closely monitor Biogen's communications for the timeline of its sNDA resubmission, as a rapid turnaround on the CMC request could limit the negative share price impact.
• The delay provides a near-term competitive advantage to rivals Novartis (NVS) and Roche (RHHBY); consider this when evaluating positions in the broader SMA treatment space.
• Given that the higher-dose approval is crucial for defending Spinraza's market share, any prolonged delay may jeopardize the already flat 2025 revenue guidance, warranting a re-evaluation of the drug's contribution to Biogen's future earnings.
• While the CRL is a negative catalyst, the fact that it is a non-clinical issue may present a buying opportunity for long-term investors if the stock overcorrects, contingent on a clear and short resolution pathway.